Washington, DC – April 5, 2024 – Cooley successfully overturned a Hatch-Waxman injunction for Liquidia Technologies, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products, enabling Liquidia to launch its new drug, Yutrepia.
On March 28, 2024, the US District Court for the District of Delaware granted Liquidia’s Rule 60 motion seeking post-judgment relief to modify portions of the court’s final judgment that blocked the final Food and Drug Administration (FDA) approval of Liquidia’s new drug application for Yutrepia. With this decision, the last remaining patent roadblock preventing final FDA approval of Yutrepia has been lifted, paving the way for Liquidia to launch its first product and meet the needs of pulmonary arterial hypertension patients.
Cooley partners Sanya Sukduang and Jonathan Davies led the Cooley team representing Liquidia.
Cooley previously advised Liquidia on its $53 million initial public offering in August 2018. The team also secured an accolade on The American Lawyer’s Litigation Daily Litigator of the Week Runners-Up and Shout Outs list for securing a win with the US Court of Appeals for the Federal Circuit when it upheld a decision by the Patent Trial and Appeal Board invalidating a patent that United Therapeutics asserted against Liquidia.
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.
